3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
4
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
36
Breast Neoplasms
32
Rectal Neoplasms
25
Esophageal Neoplasms
21
Uterine Cervical Neoplasms
20
Head and Neck Neoplasms
20
Central Nervous System Neoplasms
19
Lung Neoplasms
18
Prostatic Neoplasms
17
Lymphoma
17
Esophageal Squamous Cell Carcinoma
17
Leukemia
16
Glioblastoma
16
Squamous Cell Carcinoma of Head and Neck
15
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Carcinoma, Hepatocellular
12
Sarcoma
10
Neuroblastoma
10
Neoplasms
10
Nasopharyngeal Carcinoma
10
Brain Neoplasms
10
Astrocytoma
10
Colorectal Neoplasms
9
Pancreatic Neoplasms
7
Glioma
7
Neoplasm Metastasis
6
Nasopharyngeal Neoplasms
6
Lymphoma, Non-Hodgkin
6
Stomach Neoplasms
5
Recurrence
5
Interventions
Epirubicin
3
Gemcitabine
2
tislelizumab
1
lornoxicam
1
catumaxomab
1
avelumab
1
apatorsen
1
VB4-845
1
Ty21a typhoid vaccine
1
Therapeutics
1
Radiotherapy
1
Postoperative Period
1
Ofloxacin
1
Multiparametric Magnetic Resonance Imaging
1
Mitomycin
1
Docetaxel
1
Cystoscopy
1
BCG Vaccine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Non-Muscle Invasive Bladder Neoplasms
×
Radiotherapy
×
Clear all
NCT03950362
2019-05-16
PREVERT
Institut Paoli-Calmettes
Phase 2
Unknown
67 enrolled